PuraCath Medical™ to Present UV Disinfection Breakthroughs at Four Major Clinical Conferences in 2025

March 27, 2025

PuraCath Medical^TM, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today its participation in four prominent clinical conferences in 2025. The company will join healthcare professionals and industry experts to present its latest advancements in UV disinfection technology and its impact on reducing Catheter-Line Associated Bloodstream Infections (CLABSIs). PuraCath Medical will be attending the following clinical conferences:

ASPEN 2025 Nutrition Science & Practice Conference
ONS 2025 Congress (Oncology Nursing Society)
NHIA 2025 Annual Conference (National Home Infusion Association)
CVAA 2025 Conference (Canadian Vascular Access Association)

At each event, PuraCath Medical will present new data on the effectiveness of its UV disinfection technology, alongside findings from simulation studies conducted with device end users.

“PuraCath Medical is excited to share 99.99% or 4-log disinfection data on its latest Firefly Disinfection Device and believes that it can be the solution to CLABSI reduction in vascular access lines worldwide” said Julia Rasooly, PuraCath Medical’s CEO.

For more information on PuraCath Medical’s clinical initiatives and conference schedule, please visit www.puracath.com

What is a CLABSI (Catheter-Line Associated Bloodstream Infection)?

A CLABSI (Catheter-Line Associated Bloodstream Infection) is a laboratory confirmed bloodstream infection related to a central line such as a central venous catheter, PICC line, midline, etc. CLABSIs are associated with a high-cost burden, accounting for approximately $46,000 per case, due to prolonged hospital stays and increased mortality. More than 250,000 CLABSIs are known to occur annually in the U.S. The most common cause of a CLABSI is due to improper aseptic techniques or lack of compliance to proper aseptic techniques, and improper management of the catheter lines during access.

About PuraCath Medical^TM

PuraCath Medical^TM, a Silicon Valley based-company, is dedicated to improving the quality of life of patients by reducing the risk of infections. The Company is utilizing its technology platform, which was spun out of Stanford University’s Biodesign program, to develop novel, easy-to-use devices designed to reduce the risk of infections in patients with catheters in order to decrease infection-related hospitalizations and their associated costs. PuraCath Medical^TM has received prestigious small business government grants from the National Institute of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) with grant ID Numbers R43AI134553 and SB1AI174371 to support these initiatives.

Julia Rasooly, PuraCath Medical^TM, http://www.puracath.com, julia@puracath.com

< Older Post

How UV Disinfection is Transforming Infection Prevention in Medical Settings

October 10, 2024

PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has published the result of its research on its ultraviolet (UV) light-based intravascular catheter connection disinfection system in the American Journal of Infection Control (AJIC), a peer-reviewed scientific journal published by Elsevier on behalf of the Association for Professionals in Infection Control and Epidemiology.

Disinfection of needleless connectors for catheters in one second using a hand-held UV device

October 9, 2024

Central Line-associated Bloodstream Infections (CLABSIs) are deadly bloodstream infections with high mortality and morbidity rates in patients with vascular catheters. In the United States, around 250,000 occur yearly. Of these, about 80,000 occur in intensive care units.

PuraCath Medical Receives 510(k) Clearance for its Needleless Connector for Vascular Access

By puracath • August 3, 2021

Device is intended for use primarily by ICU nurses during infusions in patients in a critical care setting. PuraCath Medical™, a venture-backed startup company focusing on the development of technologies to reduce infections in patients with intravascular catheters, announced today that it has received 510(k) clearance for its FireFly™ Needleless Connector from the U.S. Food […]

Why We Aren’t Using UV to Disinfect Everything—Yet

By puracath • June 16, 2020

Negative perception and costs pose obstacles to a promising technology As the coronavirus pandemic continues, a technology that has existed for over 100 years is getting renewed attention as a promising disinfection tool. Ultraviolet germicidal radiation, which uses short-wavelength UV rays to kill bacteria and viruses, is already used to disinfect the air, water, and […]

PuraCath UV Device Displays a 99.9999% Disinfection of COVID-19 Virus in 1 Second

By puracath • April 27, 2020

PuraCath has been partnered and working with a top tier BSL-3 National Laboratory, which has a premiere high containment infectious disease facilities to test its Firefly UV device for the ICU and hospitals with 2019-nCoV (the COVID-19 virus). The preliminary results show that PuraCath’s device has achieved 99.9999% disinfection with SARS-CoV-2 (the virus that is […]

PuraCath FireflyTM Can Kill Deadly Microorganisms with UV Light, Like SARS CoV-2

By puracath • March 19, 2020

President Trump has officially declared a national emergency. A novel coronavirus has been identified in Wuhan City, China and has spread worldwide. It has been named SARS CoV-2 (causing disease COVID-19) by WHO. SARS CoV-2 has officially become a global pandemic by WHO. There have already been over 170,000 confirmed cases to date with an […]

PuraCath Medical Shows Greater Than 99.99% Reduction in ‘Superbug’ Candida Auris with One Second of UVC Exposure

By puracath • June 19, 2019

JUNE 18, 2019 PuraCath Medical, a venture-backed medical device company based in Silicon Valley, announced today that it has achieved 99.99% disinfection on its vascular access Firefly disinfection technology system with Candida auris (‘superbug’), Staphylococcus aureus, and Candida albicans. “Achieving greater than 4 log disinfection in these virulent microbes with only one second of UV […]

PuraCath Medical Shows Significant Reduction in Causes of Peritonitis in Peritoneal Dialysis International Journal

By puracath • March 7, 2017

San Francisco, California (March 7, 2017) – PuraCath Medical has published the result of its recent research on its ultraviolet (UV) light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the official Journal of the International Society for Peritoneal Dialysis. PDI is a major source of knowledge in the field of peritoneal dialysis and aims […]

PuraCath Medical to Present Data on FireFly™ Peritoneal Dialysis Connector Disinfecting System during 53rd ERA-EDTA Congress

By Larry Yost • May 12, 2016

San Francisco, California (May 12, 2016) – Data being presented will support planned introduction of PuraCath Medical’s technology in the European Union. PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it will present data on its next generation version of the FireFly™ […]

PuraCath Medical Presents Data at National Kidney Foundation 2016 Spring Clinical Meetings

By Larry Yost • April 28, 2016

Boston, Massachusetts (April 28, 2016) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented data on its next generation version of the FireFly™ Peritoneal Dialysis (PD) Connector Disinfecting System during the National Kidney Foundation’s 2016 Spring Clinical Meetings held […]

site by: Deco